Novartis Venture Fund and Novo Holdings have co-led a €9m series-A funding round for Finnish developer of anti-cancer drugs Rappta Therapeutics.
Novartis Venture Fund and Novo Holdings have co-led a €9m series-A funding round for Finnish developer of anti-cancer drugs Rappta Therapeutics.